Trials / Terminated
TerminatedNCT01214174
Efficacy and Safety Study of IBI-10090 in Cataract Surgery Patients
A Multicenter, Randomized, Double-masked, Dose-ranging, Phase 2 Study to Evaluate the Efficacy and Safety of IBI-10090 in Treating Inflammation in Cataract Surgery Patients
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 42 (actual)
- Sponsor
- ICON Bioscience Inc · Industry
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
This study will test the efficacy and safety of IBI-10090 in the treatment of ocular inflammation after cataract surgery.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IBI-10090 |
Timeline
- Start date
- 2010-10-01
- Primary completion
- 2012-05-01
- Completion
- 2012-05-01
- First posted
- 2010-10-04
- Last updated
- 2013-09-18
- Results posted
- 2013-09-18
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01214174. Inclusion in this directory is not an endorsement.